Steve Seedhouse

Stock Analyst at Cantor Fitzgerald

(1.95)

# 3,146

Out of 5,113 analysts

12

Total ratings

45.45%

Success rate

-2.21%

Average return

Main Sectors:

Top Industries:

Biotechnology Drug Manufacturers - Specialty & Generic

Stocks Rated by Steve Seedhouse

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	APLS Apellis Pharmaceuticals	Maintains: Overweight	$39 → $35	$23.41	+49.51%	2	Jan 13, 2026
	WVE Wave Life Sciences	Maintains: Overweight	$12 → $34	$13.26	+156.41%	1	Dec 9, 2025
	BLTE Belite Bio	Assumes: Overweight	$154	$166.93	-7.75%	1	Nov 24, 2025
	KRRO Korro Bio	Downgrades: Neutral	n/a	$11.19	-	1	Nov 13, 2025
	XNCR Xencor	Maintains: Overweight	$40 → $42	$12.84	+227.10%	2	Nov 6, 2025
	INVA Innoviva	Maintains: Overweight	$29 → $31	$19.66	+57.68%	2	Nov 6, 2025
	CAMP Camp4 Therapeutics	Initiates: Overweight	$7	$3.74	+87.24%	1	Oct 2, 2025
	TVRD Tvardi Therapeutics	Initiates: Overweight	$52	$4.33	+1,100.92%	1	Jul 11, 2025
	HROW Harrow	Initiates: Overweight	$76	$43.78	+73.60%	1	Jul 11, 2025

Apellis Pharmaceuticals

Jan 13, 2026

Maintains: Overweight

Price Target: $39 → $35

Current: $23.41

Upside: +49.51%

Wave Life Sciences

Dec 9, 2025

Maintains: Overweight

Price Target: $12 → $34

Current: $13.26

Upside: +156.41%

Belite Bio

Nov 24, 2025

Assumes: Overweight

Price Target: $154

Current: $166.93

Upside: -7.75%

Korro Bio

Nov 13, 2025

Downgrades: Neutral

Price Target: n/a

Current: $11.19

Upside: -

Xencor

Nov 6, 2025

Maintains: Overweight

Price Target: $40 → $42

Current: $12.84

Upside: +227.10%

Innoviva

Nov 6, 2025

Maintains: Overweight

Price Target: $29 → $31

Current: $19.66

Upside: +57.68%

Camp4 Therapeutics

Oct 2, 2025

Initiates: Overweight

Price Target: $7

Current: $3.74

Upside: +87.24%

Tvardi Therapeutics

Jul 11, 2025

Initiates: Overweight

Price Target: $52

Current: $4.33

Upside: +1,100.92%

Harrow

Jul 11, 2025

Initiates: Overweight

Price Target: $76

Current: $43.78

Upside: +73.60%